HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00588731

Cannabidiol or placebo added to antipsychotics for cognition in schizophrenia

About this titleRead the official source — NCT00588731
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
New HavenSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateFebruary 2009
Recruitment status
Completed
Enrollment listed in the registry
41
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00588731
Official title
Show the full official title

Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Did this study involve medication?

Yes. The study involved medication, including Cannabidiol and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies